Aegerion Pharmaceuticals, Inc. (AEGR): Sarissa Capital Management Files Amended 13D

Item 1.  Security and Issuer.

This statement constitutes Amendment No. 4 to the Schedule 13D (this “Amendment No. 4”) relating to the Common Stock, par value $0.001 (the “Shares”), issued by Aegerion Pharmaceuticals, Inc. (the “Issuer”), and hereby amends the Schedule 13D filed with the Securities and Exchange Commission on February 5, 2015 and amended by Amendments No. 1, 2 and 3 thereto (as amended, the “Initial Schedule 13D”), on behalf of the Reporting Persons (as defined in the Initial Schedule 13D), to furnish the additional information set forth herein.  All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Initial Schedule 13D.

Item 4.  Purpose of Transaction.
Item 4 of the Initial Schedule 13D is hereby amended by adding the following:

Pursuant to the Nomination Agreement (the “Nomination Agreement”) entered into on March 29, 2015, by and among the Reporting Persons and the Issuer, the parties thereto agreed that, upon the request of the Reporting Persons, the Issuer would enter into a confidentiality agreement with the Reporting Persons governing the provision of the Issuer’s confidential information to the Reporting Persons.  On October 22, 2015, the Reporting Persons and the Issuer entered into such confidentiality agreement (the “Confidentiality Agreement”).

A copy of the Confidentiality Agreement is filed herewith as an exhibit and incorporated herein by reference, and any description herein of the Confidentiality Agreement is qualified in its entirety by reference to the Confidentiality Agreement filed herewith.  A copy of the Nomination Agreement was filed as an exhibit to Amendment No. 1 of the Initial Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission on April 1, 2015 and is incorporated herein by reference, and any description herein of the Nomination Agreement is qualified in its entirety by reference to the Nomination filed therewith.

Item 7.  Material to Be Filed as Exhibits.
Items 7 of the Initial Schedule 13D is hereby amended by adding the following:
1            Confidentiality Agreement